CEPHALOSPORINS AS A POTENTIAL RISK FACTOR FOR UROLITHIASIS: A CASE-CONTROL STUDY

KRISHNAKUMAR, JANARTHANAM and GANDHIMATHI, R (2025) CEPHALOSPORINS AS A POTENTIAL RISK FACTOR FOR UROLITHIASIS: A CASE-CONTROL STUDY. Asian Journal of Pharmaceutical and Clinical Research. pp. 1-3. ISSN 0974-2441

[thumbnail of AJPCR_53944_20250405_V1.pdf] Text
AJPCR_53944_20250405_V1.pdf

Download (467kB)

Abstract

CEPHALOSPORINS AS A POTENTIAL RISK FACTOR FOR UROLITHIASIS: A CASE-CONTROL STUDY KRISHNAKUMAR JANARTHANAM GANDHIMATHI R

The study aimed to explore the impact of Oxalobacter formigenes colonization and cephalosporin antibiotic treatment on urinary oxalate, calcium, and citrate levels, with a focus on evaluating the bacterium’s role in mitigating the risk of calcium oxalate kidney stone formation. An observational, case-control study was conducted involving 350 control subjects and 280 kidney stone patients. Participants were stratified based on recent cephalosporin use and O. Formigenes colonization. Results demonstrated that O. Formigenes colonized individuals consistently exhibited lower urinary oxalate and calcium levels and higher citrate levels compared to non-colonized counterparts. Cephalosporin treatment exacerbated urinary biochemical imbalances, further increasing oxalate and calcium excretion while reducing citrate levels, particularly in non-colonized individuals. This highlights the protective role of O. Formigenes in maintaining urinary biochemical homeostasis and reducing kidney stone risk. The findings underscore the need for strategies to preserve gut microbiota, especially O. Formigenes, during antibiotic therapy to mitigate metabolic consequences and prevent urolithiasis.
04 07 2025 1 3 http://creativecommons.org/licenses/by/4.0 10.22159/ajpcr.2025v18i4.53944 https://journals.innovareacademics.in/index.php/ajpcr/article/view/53944 https://journals.innovareacademics.in/index.php/ajpcr/article/download/53944/31868 https://journals.innovareacademics.in/index.php/ajpcr/article/download/53944/31868 10.22159/ijcpr.2018v10i3.27225 Naveen V, Siddiq A, Chandana G. A study on drug utilization pattern of cephalosporins in general medicine and surgical inpatient department. Int J Curr Pharm Res. 2018;10(3):33-6. 10.22159/ajpcr.2020.v13i9.38403 Joshi A, Khumbani U, Ganjiwale J, Ganguly B. Prescribing patterns of cephalosporin in children following implementation of antibiotic stewardship program in a tertiary care hospital at Western India. Asian J Pharm Clin Res. 2020;13(9):110-4. 10.1038/ki.2013.41 Ivanovski O, Drüeke TB. A new era in the treatment of calcium oxalate stones? Kidney Int. 2013;83(6):998-1000. 10.1038/s41585-022-00647-5 Miller AW, Penniston KL, Fitzpatrick K, Agudelo J, Tasian G, Lange D. Mechanisms of the intestinal and urinary microbiome in kidney stone disease. Nat Rev Urol. 2022;19(12):695-707. 10.4103/iju.IJU_20_20 Sharma AP, Burton J, Filler G, Dave S. Current update and future directions on gut microbiome and nephrolithiasis. Indian J Urol. 2020;36(4):262-9. 10.3390/nu12020548 Ticinesi A, Nouvenne A, Chiussi G, Castaldo G, Guerra A, Meschi T. Calcium oxalate nephrolithiasis and gut microbiota: Not just a gut-kidney axis. A nutritional perspective. Nutrients. 2020;12(2):548. 10.1681/ASN.2018040402 Nazzal L, Blaser MJ. Does the receipt of antibiotics for common infectious diseases predispose to kidney stones? A cautionary note for all health care practitioners. J Am Soc Nephrol. 2018;29(6):1590-2. Sodimbaru V, Pujari L. Urolithiasis-an update review over genetics, pathophysiology and its clinical management. Int J Pharm Pharm Sci. 2014;6(11):24-31. 10.1007/s00467-022-05591-5 Ariceta G, Collard L, Abroug S, Moochhala SH, Gould E, Boussetta A, et al. ePHex: A phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria. Pediatr Nephrol. 2023;38(2):403-15. 10.5414/CN109980 Yang Y, Sharma PD, Nair V, Jhaveri KD, Malieckal DA, Wanchoo R, et al. Kidney oxalate crystal deposition in adult patients: A relatively common finding. Clin Nephrol. 2020;93(5):243-50. 10.1007/978-1-84800-362-0_19 Daudon M, Jungers P. Drug-induced renal stones. In: Urinary Tract Stone Disease. London: Springer; 2010. p. 225-37. 10.1007/s11255-020-02627-3 Ravikumar Y, Begum RF, Velmurugan R. Oxalobacter formigenes reduce the risk of kidney stones in patients exposed to oral antibiotics: A case-control study. Int Urol Nephrol. 2021;53(1):13-20. 10.1016/j.micpath.2021.105257 Bostanghadiri N, Ziaeefar P, Sameni F, Mahmoudi M, Hashemi A, Darban-Sarokhalil D. The controversial association of gut and urinary microbiota with kidney stone formation. Microb Pathog. 2021;161:105257. 10.3390/microorganisms12061098 Joubran P, Roux FA, Serino M, Deschamps JY. Gut and urinary microbiota in cats with kidney stones. Microorganisms. 2024;12(6):1098. 10.1186/s12882-020-01805-w Stanford J, Charlton K, Stefoska-Needham A, Ibrahim R, Lambert K. The gut microbiota profile of adults with kidney disease and kidney stones: A systematic review of the literature. BMC Nephrol. 2020;21(1):215. 10.1038/ki.2013.104 Siener R, Bangen U, Sidhu H, Hönow R, Von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013;83:1144-9. 10.1053/j.ajkd.2019.07.021 Tasian G, Miller A, Lange D. Antibiotics and kidney stones: Perturbation of the gut-kidney axis. Am J Kidney Dis. 2019;74(6):724-6. 10.1067/mpd.2002.120694 Böhles H, Gebhardt B, Beeg T, Sewell AC, Solem E, Posselt G. Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis. J Pediatr. 2002;140(1):103-9. 10.1016/S0889-8529(02)00030-0 Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31(4):927-49.

Item Type: Article
Subjects: Pharmaceutics > Drug Delivery System
Domains: Pharmaceutics
Depositing User: Mr IR Admin
Date Deposited: 20 Aug 2025 05:14
Last Modified: 20 Aug 2025 05:14
URI: https://ir.vistas.ac.in/id/eprint/10025

Actions (login required)

View Item
View Item